$EWTX
Edgewise Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022001850 Filed on February 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.734M $11.03M $1.205M
YoY Change 209.88% 398.91%
% of Gross Profit
Research & Development $9.088M $32.19M $5.140M
YoY Change 76.81% 114.84%
% of Gross Profit
Depreciation & Amortization $78.00K $300.0K $50.00K
YoY Change 56.0% 50.0%
% of Gross Profit
Operating Expenses $12.82M $43.22M $6.344M
YoY Change 102.11% 151.37%
Operating Profit -$43.22M
YoY Change 151.37%
Interest Expense $126.0K $402.0K $2.000K
YoY Change 6200.0% 474.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.70M -$42.81M -$6.342M
YoY Change 100.19% 150.08%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.70M -$42.81M -$6.342M
YoY Change 100.19% 150.03%
Net Earnings / Revenue
Basic Earnings Per Share -$1.14
Diluted Earnings Per Share -$256.5K -$1.14 -$133.3K
COMMON SHARES
Basic Shares Outstanding 49.30M 37.53M
Diluted Shares Outstanding 37.53M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $280.8M $280.8M $129.1M
YoY Change 117.51% 117.5%
Cash & Equivalents $15.57M $15.57M $104.9M
Short-Term Investments $265.2M $265.2M $24.18M
Other Short-Term Assets $2.984M $2.984M
YoY Change 397.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $283.8M $283.8M $129.6M
YoY Change 118.88% 118.96%
LONG-TERM ASSETS
Property, Plant & Equipment $912.0K $912.0K $516.0K
YoY Change 76.74% 82.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $548.0K $548.0K $975.0K
YoY Change -43.79% -45.2%
Total Long-Term Assets $1.460M $1.460M $1.491M
YoY Change -2.08% -2.67%
TOTAL ASSETS
Total Short-Term Assets $283.8M $283.8M $129.6M
Total Long-Term Assets $1.460M $1.460M $1.491M
Total Assets $285.2M $285.2M $131.1M
YoY Change 117.51% 117.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.843M $3.843M $1.580M
YoY Change 143.23% 140.19%
Accrued Expenses $3.881M $6.678M $1.587M
YoY Change 144.55% 138.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.52M $10.52M $4.342M
YoY Change 142.31% 144.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $329.0K $329.0K
YoY Change
Total Long-Term Liabilities $329.0K $329.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.52M $10.52M $4.342M
Total Long-Term Liabilities $329.0K $329.0K
Total Liabilities $10.85M $10.85M $4.342M
YoY Change 149.88% 152.33%
SHAREHOLDERS EQUITY
Retained Earnings -$76.96M -$34.15M
YoY Change 125.38%
Common Stock $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $274.4M $274.4M -$33.42M
YoY Change
Total Liabilities & Shareholders Equity $285.2M $285.2M $131.1M
YoY Change 117.51% 117.57%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$12.70M -$42.81M -$6.342M
YoY Change 100.19% 150.03%
Depreciation, Depletion And Amortization $78.00K $300.0K $50.00K
YoY Change 56.0% 50.0%
Cash From Operating Activities -$9.419M -$33.51M -$4.638M
YoY Change 103.08% 128.97%
INVESTING ACTIVITIES
Capital Expenditures -$79.00K $668.0K $0.00
YoY Change 229.06%
Acquisitions
YoY Change
Other Investing Activities $14.20M -$241.6M -$24.18M
YoY Change -158.73% 899.0%
Cash From Investing Activities $14.12M -$242.2M -$24.18M
YoY Change -158.4% 893.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 293.0K 186.4M 95.00M
YoY Change -99.69% 54.96%
NET CHANGE
Cash From Operating Activities -9.419M -33.51M -4.638M
Cash From Investing Activities 14.12M -242.2M -24.18M
Cash From Financing Activities 293.0K 186.4M 95.00M
Net Change In Cash 4.995M -89.35M 66.19M
YoY Change -92.45% -209.95%
FREE CASH FLOW
Cash From Operating Activities -$9.419M -$33.51M -$4.638M
Capital Expenditures -$79.00K $668.0K $0.00
Free Cash Flow -$9.340M -$34.18M -$4.638M
YoY Change 101.38% 130.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37526332
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
739004
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37526332
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
739004
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001710072
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1009479
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49500308
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.14
CY2020 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-23.17
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.17
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40236
CY2021 dei Entity Registrant Name
EntityRegistrantName
Edgewise Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1725586
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
3415 Colorado Ave.
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80303
CY2021 dei City Area Code
CityAreaCode
720
CY2021 dei Local Phone Number
LocalPhoneNumber
262-7002
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
EWTX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
653400000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49511959
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Denver, Colorado
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15566000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104916000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
265223000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
24178000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2984000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
551000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
283773000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
129645000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1614000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
946000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
702000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
430000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
912000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
516000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
548000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
975000
CY2021Q4 us-gaap Assets
Assets
285233000
CY2020Q4 us-gaap Assets
Assets
131136000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3843000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1580000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2797000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1175000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3881000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1587000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10521000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4342000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
329000
CY2021Q4 us-gaap Liabilities
Liabilities
10850000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Liabilities
Liabilities
4342000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
160214000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
88000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49500308
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1009479
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
351852000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
727000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-514000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76960000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34147000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
274383000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-33420000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
285233000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131136000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32189000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14983000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11026000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2209000
CY2021 us-gaap Operating Expenses
OperatingExpenses
43215000
CY2020 us-gaap Operating Expenses
OperatingExpenses
17192000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-43215000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-17192000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
402000
CY2020 us-gaap Interest Income Other
InterestIncomeOther
69000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
402000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
69000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42813000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17123000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-514000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43327000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17123000
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.14
CY2020 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-23.17
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37526332
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
739004
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-16853000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
202000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
354000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
248000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4404000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-514000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17123000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-33420000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
160214000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
186148000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
116000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42813000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
274383000
CY2021 us-gaap Profit Loss
ProfitLoss
-42813000
CY2020 us-gaap Profit Loss
ProfitLoss
-17123000
CY2021 us-gaap Depreciation
Depreciation
272000
CY2020 us-gaap Depreciation
Depreciation
185000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4404000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
354000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2392000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
417000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2654000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
521000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1622000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
842000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2746000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1004000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33507000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14634000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
288203000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24178000
CY2021 ewtx Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
3444000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43200000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
668000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
203000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-242227000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24381000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
186148000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
124000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
202000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
248000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186384000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120278000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-89350000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
81263000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104916000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23653000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15566000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104916000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
160214000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.018
CY2020 ewtx Deferred Offering Costs Included In Accounts Payable And Accrued Other Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedOtherExpenses
719000
CY2020 ewtx Preferred Stock Issuance Costs In Accrued Other Expenses
PreferredStockIssuanceCostsInAccruedOtherExpenses
124000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1  DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Edgewise Therapeutics, Inc. (the Company) was incorporated as a Delaware corporation in May 2017, and it is headquartered in Boulder, Colorado. The Company is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. The Company’s lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of genetically defined muscle disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Initial Public Offering and Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">On March 30, 2021, the Company completed its initial public offering (IPO) in which it issued and sold 12,650,000 shares of common stock at a price of $16.00 per share, including 1,650,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO was $186.1 million after deducting underwriting discounts and commissions of $14.2 million and offering expenses of approximately $2.1 million. In addition, in connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into 35,557,569 shares of common stock. On March 19, 2021, the Company amended its certificate of incorporation to effect a 1-for-<span style="-sec-ix-hidden:Hidden_ip6pV0qyVESorh-HFMsDTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8932</span></span> reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying financial statements and related notes give retroactive effect to the reverse stock split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks and Uncertainties </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">In March 2020, the World Health Organization declared the novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations. Disruptions caused by the COVID-19 pandemic, including the effects of the stay-at-home orders and work-from-home policies, have impacted productivity, have resulted in increased operational expenses, certain adjustments to the operations of the Company’s clinical trial, the suspension of enrollment of new patients at the Company’s clinical trial site, and delays in certain supply chain activities and collecting and analyzing data from patients in the Company’s clinical trial, and may further disrupt the business and delay the development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct business in the ordinary course as well as the spread, severity and potential resurgence of COVID-19, the impact of new COVID-19 variants, and vaccination deployment efforts. As a result, research and development expenses and general and administrative expenses may vary significantly if there is an increased impact from COVID-19 on the costs and timing associated with the conduct of the clinical trial and other related business activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">The Company has an accumulated deficit of $77.0 million and, cash, cash equivalents and marketable securities of $280.8 million as of December 31, 2021. The Company’s ability to fund ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities and issuing debt or other financing vehicles. The Company’s ability to secure capital is dependent upon success in developing its technology and product candidates. The Company cannot provide assurance that additional capital will be available on acceptable terms, if at all. The issuance of additional equity or debt securities will likely result in substantial dilution to the Company’s stockholders. Should additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from the Company’s assets or discharge liabilities in the normal course of business, which may, among other alternatives, cause the Company to delay, substantially reduce, or discontinue operational activities to conserve </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">cash balances, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company believes that the $280.8 million of cash, cash equivalents and marketable securities on hand as of December 31, 2021 will be sufficient to fund its operations in the normal course of business and meet its liquidity needs through at least the next 12 months from the issuance of these financial statements.</p>
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77000000.0
CY2021Q4 ewtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
280800000
CY2021Q4 ewtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
280800000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on deposits since inception. The Company regularly invests excess cash with major financial institutions in money market funds, corporate debt securities, and commercial paper, all of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are of high credit rating.</p>
CY2021 us-gaap Depreciation
Depreciation
300000
CY2020 us-gaap Depreciation
Depreciation
200000
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
184800000
CY2021Q4 ewtx Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
80900000
CY2021Q4 ewtx Shares Authorized Total
SharesAuthorizedTotal
1200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 ewtx Number Of Votes Per Share
NumberOfVotesPerShare
1
CY2021 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.080
CY2021 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.750
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4404000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
354000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
110000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
77000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
141000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.273
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.264
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
14570000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
7117000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3187000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1240000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1130000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
398000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
773000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
771000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
39000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
141000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
90000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
42000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
34000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20530000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8850000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20530000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8850000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
69400000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
33900000
CY2020Q4 ewtx Percentage Of Valuation Allowance To Net Deferred Tax Assets
PercentageOfValuationAllowanceToNetDeferredTaxAssets
100
CY2021Q4 ewtx Percentage Of Valuation Allowance To Net Deferred Tax Assets
PercentageOfValuationAllowanceToNetDeferredTaxAssets
100
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11700000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4500000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
47000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
285000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3881000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42813000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17123000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37526332
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
739004
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.17
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16863218
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23851390
CY2021Q4 ewtx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3470000
CY2020Q4 ewtx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
550000
CY2020Q4 ewtx Accrued Issuance Cost Current
AccruedIssuanceCostCurrent
452000
CY2020Q4 ewtx Accrued License Fees Current
AccruedLicenseFeesCurrent
300000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
411000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1587000

Files In Submission

Name View Source Status
0001558370-22-001850-index-headers.html Edgar Link pending
0001558370-22-001850-index.html Edgar Link pending
0001558370-22-001850.txt Edgar Link pending
0001558370-22-001850-xbrl.zip Edgar Link pending
ewtx-20211231.xsd Edgar Link pending
ewtx-20211231x10k.htm Edgar Link pending
ewtx-20211231x10k006.jpg Edgar Link pending
ewtx-20211231x10k007.jpg Edgar Link pending
ewtx-20211231x10k008.jpg Edgar Link pending
ewtx-20211231x10k009.jpg Edgar Link pending
ewtx-20211231x10k010.jpg Edgar Link pending
ewtx-20211231x10k011.jpg Edgar Link pending
ewtx-20211231x10k012.jpg Edgar Link pending
ewtx-20211231x10k013.jpg Edgar Link pending
ewtx-20211231x10k014.jpg Edgar Link pending
ewtx-20211231x10k015.jpg Edgar Link pending
ewtx-20211231x10k016.jpg Edgar Link pending
ewtx-20211231x10k017.jpg Edgar Link pending
ewtx-20211231x10k018.jpg Edgar Link pending
ewtx-20211231x10k019.jpg Edgar Link pending
ewtx-20211231x10k020.jpg Edgar Link pending
ewtx-20211231x10k021.jpg Edgar Link pending
ewtx-20211231x10k022.jpg Edgar Link pending
ewtx-20211231x10k023.jpg Edgar Link pending
ewtx-20211231x10k024.jpg Edgar Link pending
ewtx-20211231x10k025.jpg Edgar Link pending
ewtx-20211231x10k026.jpg Edgar Link pending
ewtx-20211231x10k027.jpg Edgar Link pending
ewtx-20211231x10k028.jpg Edgar Link pending
ewtx-20211231x10k029.jpg Edgar Link pending
ewtx-20211231x10k030.jpg Edgar Link pending
ewtx-20211231x10k031.jpg Edgar Link pending
ewtx-20211231x10k032.jpg Edgar Link pending
ewtx-20211231x10k033.jpg Edgar Link pending
ewtx-20211231x10k034.jpg Edgar Link pending
ewtx-20211231x10k035.jpg Edgar Link pending
ewtx-20211231x10k036.jpg Edgar Link pending
ewtx-20211231x10k037.jpg Edgar Link pending
ewtx-20211231x10k038.jpg Edgar Link pending
ewtx-20211231x10k039.jpg Edgar Link pending
ewtx-20211231x10k040.jpg Edgar Link pending
ewtx-20211231x10k041.jpg Edgar Link pending
ewtx-20211231x10k042.jpg Edgar Link pending
ewtx-20211231x10k043.jpg Edgar Link pending
ewtx-20211231x10k044.jpg Edgar Link pending
ewtx-20211231x10k045.jpg Edgar Link pending
ewtx-20211231x10k046.jpg Edgar Link pending
ewtx-20211231x10k047.jpg Edgar Link pending
ewtx-20211231x10k048.jpg Edgar Link pending
ewtx-20211231x10k049.jpg Edgar Link pending
ewtx-20211231x10k_htm.xml Edgar Link completed
ewtx-20211231xex23d1.htm Edgar Link pending
ewtx-20211231xex31d1.htm Edgar Link pending
ewtx-20211231xex31d2.htm Edgar Link pending
ewtx-20211231xex32d1.htm Edgar Link pending
ewtx-20211231xex4d3.htm Edgar Link pending
ewtx-20211231_cal.xml Edgar Link unprocessable
ewtx-20211231_def.xml Edgar Link unprocessable
ewtx-20211231_lab.xml Edgar Link unprocessable
ewtx-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending